The estimated Net Worth of Robert S Epstein is at least $6.68 Milhão dollars as of 24 May 2023. Robert Epstein owns over 7,600 units of Illumina Inc stock worth over $1,842,990 and over the last 12 years he sold ILMN stock worth over $4,338,084. In addition, he makes $497,617 as Independent Director at Illumina Inc.
Robert has made over 30 trades of the Illumina Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 7,600 units of ILMN stock worth $540,284 on 24 May 2023.
The largest trade he's ever made was exercising 10,000 units of Illumina Inc stock on 13 July 2020 worth over $52,800. On average, Robert trades about 781 units every 43 days since 2012. As of 24 May 2023 he still owns at least 14,764 units of Illumina Inc stock.
You can see the complete history of Robert Epstein stock trades at the bottom of the page.
Dr. Robert S. (Rob) Epstein, M.D. is an Independent Director of Illumina Inc. since November 29, 2012. Dr. Epstein is an epidemiologist who worked in public health and academia before joining the private sector. Prior to this role, Dr. Epstein was Medco’s Chief Medical Officer for 13 years, where he led formulary development, clinical guideline development, drug information services, personalized medicine program development, and client analytics and reporting. Dr. Epstein is also the former President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and has served on the board of directors of the Drug Information Association (DIA) and the International Society of Quality of Life. Dr. Epstein serves as a director of AVEO Pharmaceuticals, Inc. a NASDAQ-listed cancer therapeutics company, and Proteus Digital Health, a privately-held healthcare technology company. Dr. Epstein has published more than 75 peer-reviewed medical articles and book chapters and serves as a reviewer for several influential medical journals, including the New England Journal of Medicine and JAMA (The Journal of the American Medical Association). Dr. Epstein received his medical degree and B.S. in Biomedical Science from the University of Michigan and an M.S. in preventative medicine from the University of Maryland. In selecting Dr. Epstein as a past nominee for election to the Board of Directors, the Board considered, among other things, Dr. Epstein’s in-depth experience and practical knowledge of how molecular diagnostic tests are reimbursed and the issues raised by payors and other evidentiary authorities. As our technology and products are increasingly utilized in clinical settings, Dr. Epstein’s experience will contribute to the Board’s understanding of these markets and the risks and opportunities associated with operating in markets regulated by the U.S. Food and Drug Administration.
As the Independent Director of Illumina Inc, the total compensation of Robert Epstein at Illumina Inc is $497,617. There are 14 executives at Illumina Inc getting paid more, with Mostafa Ronaghi having the highest compensation of $3,541,310.
Robert Epstein is 64, he's been the Independent Director of Illumina Inc since 2012. There are 2 older and 20 younger executives at Illumina Inc. The oldest executive at Illumina Inc is John Thompson, 71, who is the Lead Independent Director.
Robert's mailing address filed with the SEC is 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 21 years, insiders at Illumina Inc have traded over $412,190,379 worth of Illumina Inc stock and bought 13,386 units worth $1,243,499 . The most active insiders traders include John Wendell Thompson, Jay T Flatley, eRobert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of $954,700. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth $991,676.
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina Inc executives and other stock owners filed with the SEC include: